Physician profile
Robert D Campagna
NPI 1598775603
$1,801.24
in general payments reported to CMS, 2019-2025
17 companies · $74.16 in 2025
The $74.16 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $410 · 2022: $228 · 2023: $158 · 2024: $259 · 2025: $74.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.16 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $370.34 | 2019-2020 | |
| Biotronik INC. | $324.00 | 2023-2024 | Amvia Edge, Acticor 7 Vr-T Dx |
| Atricure, INC. | $187.64 | 2022 | |
| Amarin Pharma, INC. | $168.04 | 2019-2020 | |
| Amgen INC. | $149.77 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $138.79 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $93.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $69.75 | 2019-2020 | |
| Lilly USA, LLC | $68.42 | 2022-2025 | |
| Pfizer INC. | $49.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2019 | |
| Astellas Pharma US INC | $36.93 | 2019-2020 | |
| Sanofi Pasteur INC. | $17.62 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.13 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.47 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Campagna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.